Table 2.

Patient- and disease-related determinants of dietary intake less than normal

	N	Univariate		Multivariate model 1		Multivariate model 2
		OR [95% CI]	p	OR [95% CI]	p	OR [95% CI]	p
Sex (male = reference)	1126	1.33 [1.05, 1.69]	0.017	1.38 [1.06, 1.79]	0.017	1.38 [1.06, 1.78]	0.015
Age (years)			0.151
< 30	10	2.28 [0.58, 8.96]	0.239
30–39	33	0.81 [0.40, 1.67]	0.574
40–49	107	0.89 [0.58, 1.38]	0.052
50–59	192	1.43 [1.00, 2.04]	0.597
60–69	336	Reference
70–79	300	1.16 [0.85, 1.59]	0.346
80–89	133	1.57 [1.04, 2.37]	0.031
90–99	17	1.40 [0.52, 3.75]	0.510
Cancer stage			0.008		0.010		0.007
Carcinoma in situ/stage I	249	Reference		Reference		Reference
II	180	1.10 [0.75, 1.61]	0.637	1.09 [0.71, 1.66]	0.697	1.06 [0.70, 1.60]	0.781
III	177	1.52 [1.03, 2.25]	0.033	1.45 [0.94, 2.24]	0.092	1.52 [1.00, 2.30]	0.050
IV	418	1.61 [1.17, 2.21]	0.003	1.62 [1.09, 2.41]	0.018	1.70 [1.20, 2.40]	0.003
Missing	107	1.85 [1.16, 2.93]	0.009	2.28 [1.34, 3.86]	0.002	1.90 [1.16, 3.11]	0.011
Therapy situation			0.001		0.380
Diagnosis	89	Reference		Reference
Surgery	346	1.18 [0.74, 1.87]	0.497	1.12 [0.67, 1.89]	0.659
Radiotherapy	36	1.28 [0.59, 2.78]	0.536	1.11 [0.47, 2.63]	0.815
Complications	76	1.66 [0.89, 3.09]	0.111	1.18 [0.60, 2.36]	0.629
Palliative	96	2.48 [1.36, 4.55]	0.003	1.70 [0.84, 3.45]	0.140
Multiple	141	1.75 [1.02, 3.00]	0.041	1.48 [0.81, 2.71]	0.203
Systemic treatment	305	0.93 [0.58, 1.49]	0.753	1.05 [0.61, 1.80]	0.868
Missing	42	0.70 [0.33, 1.46]	0.338	0.63 [0.28, 1.45]	0.280
Therapy goal			0.015		0.265
Curative	684	Reference		Reference
Palliative	420	1.37 [1.07, 1.75]	0.012	0.96 [0.69, 1.34]	0.817
Missing	27	0.64 [0.29, 1.40]	0.265	0.48 [0.19, 1.16]	0.103
Duration since admission (days)			< 0.001		0.001		< 0.001
< 4	379	Reference		Reference		Reference
4–7	232	2.11 [1.51, 2.94]	< 0.001	1.83 [1.26, 2.65]	0.001	1.91 [1.34, 2.73]	< 0.001
8–21	341	2.40 [1.78, 3.24]	< 0.001	1.96 [1.38, 2.78]	< 0.001	1.97 [1.42, 2.73]	< 0.001
> 21	169	2.28 [1.57, 3.30]	< 0.001	1.83 [1.19, 2.82]	0.006	1.92 [1.28, 2.88]	0.002
Comorbidity (no = reference)	1131	0.96 [0.75, 1.21]	0.710
Number of drugs per day			0.006		0.504
None	132	Reference		Reference
1–2	227	1.35 [0.88, 2.08]	0.172	1.44 [0.90, 2.32]	0.131
3–5	322	1.51 [1.00, 2.27]	0.048	1.33 [0.85, 2.10]	0.211
> 5	353	2.05 [1.37, 3.08]	0.001	1.42 [0.90, 2.32]	0.128
Missing	97	1.80 [1.06, 3.05]	0.030	1.11 [0.61, 2.01]	0.734
BMI			0.002		0.372
< 18.5	100	2.00 [1.27, 3.15]	0.003	1.48 [0.90, 2.43]	0.121
18–25	516	Reference	0.795	Reference
25–30	324	1.04 [0.79, 1.37]	0.882	1.17 [0.86, 1.59]	0.326
30–35	107	1.03 [0.68, 1.57]	0.732	1.25 [0.79, 1.98]	0.345
> 35	31	0.88 [0.43, 1.82]	0.001	0.88 [0.39, 2.00]	0.765
Missing	53	2.89 [1.51, 5.54]	0.481	1.82 [0.88, 3.79]	0.108
Unintentional weight loss			< 0.001		< 0.001		< 0.001
No	387	Reference		Reference		Reference
Yes	683	2.75 [2.13, 3.56]	< 0.001	2.52 [1.90, 3.36]	< 0.001	2.56 [1.94, 3.37]	< 0.001
Missing	61	2.01 [1.17, 3.47]	0.012	1.55 [0.85, 2.86]	0.151	1.54 [0.86, 2.76]	0.145
Self-reported performance score			< 0.001		< 0.001		< 0.001
0	193	Reference		Reference		Reference
1	230	1.74 [1.17, 2.57]	0.006	1.26 [0.82, 1.93]	0.290	1.37 [0.90, 2.08]	0.143
2	294	1.98 [1.36, 2.87]	< 0.001	1.44 [0.96, 2.16]	0.079	1.56 [1.04, 2.32]	0.030
3	179	3.15 [2.06, 4.81]	< 0.001	2.13 [1.33, 3.41]	0.002	2.37 [1.50, 3.72]	< 0.001
4	166	6.27 [3.92, 10.02]	< 0.001	3.67 [2.17, 6.20]	< 0.001	4.15 [2.51, 6.86]	< 0.001
Missing	69	1.96 [1.12, 3.42]	0.018	1.56 [0.85, 2.86]	0.148	1.66 [0.93, 2.99]	0.089

Data are presented as odds ratios (OR) with 95% confidence intervals (CI). Model 1 includes all characteristics with p < 0.10 in univariate analysis, n = 1116 and R² = 0.203. Model 2 includes characteristics with p < 0.05 after backward regression, n = 1116 and R² = 0.182. Italicized data is significant at (p < 0.05)